Subsequent leukemia was associated with high cumulative doses of epipodophyllotoxins, older age at initial cancer diagnosis, and receipt of hematopoietic stem cell transplant.

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia ... Radon, Even at Levels Below EPA Guideline for Mitigation, Is Linked to Childhood Leukemia ...

"Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...

A new study reveals a modular CAR-T approach that effectively targets heterogeneous antigens in paediatric acute myeloid leukaemia, enhancing treatment success through combinatorial targeting.

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at ...

P1, the registration-directed study of luveltamab tazevibulin for pediatric patients with CBFA2T3::GLIS2 acute myeloid leukemia, has been initiated and is open for enrollment. In December 2023, Dr.

REFRaME-P1 is a registration-enabling study evaluating the efficacy and safety of luvelta in infants and children under 12 years of age with CBF/GLIS AML. This will be a global study, with the ...

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...